IRIS UniCatt

Gentile, Marino
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.409
AS - Asia 841
EU - Europa 577
SA - Sud America 176
Continente sconosciuto - Info sul continente non disponibili 36
AF - Africa 22
OC - Oceania 4
Totale 3.065
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.361
SG - Singapore 437
SE - Svezia 171
BR - Brasile 142
CN - Cina 116
IT - Italia 96
VN - Vietnam 79
FR - Francia 77
DE - Germania 70
IN - India 57
IE - Irlanda 43
GB - Regno Unito 39
ID - Indonesia 28
JP - Giappone 24
CA - Canada 20
BD - Bangladesh 15
AR - Argentina 13
MX - Messico 13
HK - Hong Kong 12
ZA - Sudafrica 11
AT - Austria 10
RU - Federazione Russa 10
TR - Turchia 10
FI - Finlandia 9
PK - Pakistan 8
PL - Polonia 8
IQ - Iraq 7
KR - Corea 7
LT - Lituania 7
UA - Ucraina 7
CO - Colombia 6
ES - Italia 6
UZ - Uzbekistan 6
JO - Giordania 5
VE - Venezuela 5
AU - Australia 4
MA - Marocco 4
NL - Olanda 4
SA - Arabia Saudita 4
BE - Belgio 3
CZ - Repubblica Ceca 3
EC - Ecuador 3
GR - Grecia 3
KZ - Kazakistan 3
LV - Lettonia 3
MY - Malesia 3
BO - Bolivia 2
CH - Svizzera 2
CL - Cile 2
DZ - Algeria 2
ET - Etiopia 2
GE - Georgia 2
JM - Giamaica 2
NI - Nicaragua 2
NP - Nepal 2
PH - Filippine 2
PR - Porto Rico 2
PS - Palestinian Territory 2
RO - Romania 2
SV - El Salvador 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AF - Afghanistan, Repubblica islamica di 1
AM - Armenia 1
AZ - Azerbaigian 1
BB - Barbados 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
CR - Costa Rica 1
CW - ???statistics.table.value.countryCode.CW??? 1
DM - Dominica 1
EG - Egitto 1
EU - Europa 1
HN - Honduras 1
IL - Israele 1
IR - Iran 1
KE - Kenya 1
LK - Sri Lanka 1
MD - Moldavia 1
MM - Myanmar 1
NG - Nigeria 1
NO - Norvegia 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PT - Portogallo 1
SY - Repubblica araba siriana 1
Totale 3.032
Salva come PNG Salva come JPEG
Città #
Singapore 280
Chandler 183
Ashburn 116
San Jose 106
New York 61
Tukwila 46
Dublin 34
Los Angeles 33
Beijing 32
Frankfurt am Main 30
Hyderabad 29
Ho Chi Minh City 27
Lauterbourg 26
Dallas 25
Jakarta 24
Tokyo 24
Princeton 21
Milan 18
Hanoi 17
San Mateo 16
São Paulo 15
Wilmington 15
Marseille 13
Düsseldorf 12
Florence 12
Hefei 12
Houston 10
Atlanta 9
Chicago 9
Dearborn 9
Hong Kong 9
London 9
Pune 9
Boston 8
Helsinki 8
Nuremberg 8
Rio de Janeiro 8
The Dalles 8
Brooklyn 7
Johannesburg 7
Norwalk 7
Phoenix 7
Seoul 7
Trieste 7
Garden City 6
Moscow 6
Orem 6
Poplar 6
Tashkent 6
Toronto 6
Amman 5
Bologna 5
Columbus 5
Fairfield 5
Lahore 5
Redwood City 5
Stockholm 5
Ankara 4
Baghdad 4
Belo Horizonte 4
Benalla 4
Cattolica 4
Chennai 4
Council Bluffs 4
Denver 4
Jacksonville 4
Manchester 4
Munich 4
Queens 4
Querétaro 4
Redmond 4
San Francisco 4
Santa Clara 4
Seattle 4
Vicopisano 4
Washington 4
Bogotá 3
Bremen 3
Brussels 3
Buffalo 3
Campinas 3
City of London 3
Dhaka 3
Falls Church 3
Fremont 3
Genoa 3
Haiphong 3
Izmir 3
Las Vegas 3
Mexico City 3
Montreal 3
Passo Fundo 3
Portsmouth 3
Riga 3
Salvador 3
Wroclaw 3
Addis Ababa 2
Andover 2
Bangkok 2
Bari 2
Totale 1.588
Salva come PNG Salva come JPEG
Nome #
Clinical Features of Patients with Cervical Artery Dissection and Fibromuscular Dysplasia 307
Adult phenotype in Koolen-de Vries/KANSL1 haploinsufficiency syndrome 300
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 165
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 157
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 138
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies 131
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 130
Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study 126
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 121
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 119
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 117
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 116
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 112
Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group 111
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 108
CD49d promotes disease progression in chronic lymphocytic leukemia: New insights from CD49d bimodal expression 107
Time to progression of mantle cell lymphoma after high-dose cytarabine-based regimens defines patients risk for death 106
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus 103
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID-19 pandemic and at the start of the vaccination program. A Campus CLL report 103
Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: A Campus CLL report 101
Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL 100
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 97
Ponatinib as second-line treatment in chronic phase chronic myeloid leukemia patients in real-life practice. 90
Totale 3.065
Salva come PNG Salva come JPEG
Categoria #
all - tutte 13.960
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 13.960
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022228 0 0 49 32 27 5 2 26 7 7 48 25
2022/2023422 58 67 30 64 18 66 15 25 55 3 12 9
2023/2024243 9 59 11 12 15 59 14 12 1 8 14 29
2024/2025472 9 13 31 19 43 20 19 15 57 96 89 61
2025/20261.257 200 37 69 162 245 69 197 55 81 61 59 22
2026/2027377 36 214 127 0 0 0 0 0 0 0 0 0
Totale 3.065